SCHEMBL144897

SCHEMBL144897

O=C(O)c1ccccc1OSSOc1ccccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.57
ALDH1A1 P00352 9/20 0.57
HSD17B10 Q99714 6/20 0.57
HPGD P15428 6/20 0.57
HMGB1 P09429 2/20 0.57
NAPRT Q6XQN6 2/20 0.57
ESR1 P03372 1/20 0.57
ITGB3 P05106 1/20 0.57
ITGA2B P08514 1/20 0.57
TSHR P16473 1/20 0.57
GGT1 P19440 1/20 0.57
PTGS1 P23219 1/20 0.57
PTGS2 P35354 1/20 0.57
BLM P54132 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
MAPT P10636 2/20 0.55
USP2 O75604 1/20 0.55
PDE3A Q14432 1/20 0.55
ALOX15 P16050 1/20 0.54
HTT P42858 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29402606 0.87 KDM4E (0.57) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL3022599 0.85 KDM4E (0.55) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL27705464 0.83 KDM4E (0.53) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL11108804 0.83 KDM4E (0.53) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL212177 0.83 KDM4E (0.58) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL9289450 0.82 KDM4E (0.52) KDM4EALDH1A1HSD17B10HPGDHMGB1
Ammonia Solution, Strong SCHEMBL28040604 0.82 KDM4E (0.56) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL3682302 0.80 KDM4E (0.59) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL11358522 0.80 KDM4E (0.56) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL1308799 0.80 KDM4E (0.54) KDM4EALDH1A1HSD17B10HPGDHMGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012169077-A1 PROCESS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2012-12-13 WO claimed
JP-9228081-A None JP disclosed
US-20140366905-A1 PROCESS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2014-12-18 US disclosed
EP-2806850-A1 PROCESS FOR TREATING KERATIN FIBERS L'Oréal (FR) 2014-12-03 EP disclosed
WO-2013111346-A1 PROCESS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2013-08-01 WO disclosed
WO-2012169077-A1 PROCESS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2012-12-13 WO disclosed
US-20120058254-A1 ELECTROLESS PLATING SOLUTION, METHOD FOR ELECTROLESS PLATING USING THE SAME AND METHOD FOR MANUFACTURING CIRCUIT BOARD C. UYEMURA & CO., LTD. (JP) 2012-03-08 US disclosed
US-7569318-B2 double hydroxide salt contains monovalent and/or divalent, and also trivalent, metal cations (Mg, Ca, Zn, Co, Ni, Fe, Cu and Mn) and an aromatic acid (benzoic acid, naphthoic acid, 4-tert-butylbenzoic acid, benzenesulfonic acid, naphthalenesulfonic acid); influence electrostatic charging in a matrix CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2009-08-04 US disclosed
US-20060020069-A1 Use of salts of layered double hydoxides CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2006-01-26 US disclosed
JP-H09228081-A PICKLING SOLUTION FOR STAINLESS STEEL AND METHOD FOR PICKLING STAINLESS STEEL USING THE SOLUTION KAWASAKI STEEL CORP 1997-09-02 JP disclosed
US-4141734-A SUBSTITUTED ORGANIC DI- OR TRISULFIDE ANTIDEPOSIT AGENTS CIBA-GEIBY AG (CH) 1979-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140366905-A1 PROCESS FOR TREATING KERATIN FIBERS KRT18, CKAP4, HSPA4L KDM4E 161/4885ALDH1A1 791/4885HSD17B10 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.